标题
Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
作者
关键词
-
出版物
Cancers
Volume 13, Issue 11, Pages 2666
出版商
MDPI AG
发表日期
2021-05-28
DOI
10.3390/cancers13112666
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway
- (2020) Kari J. Kurppa et al. CANCER CELL
- Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer
- (2020) Adam J Schoenfeld et al. CLINICAL CANCER RESEARCH
- Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
- (2020) Lecia V Sequist et al. LANCET ONCOLOGY
- Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
- (2020) Jenny Y. Xue et al. NATURE
- TEMPORARY REMOVAL: Updated overall survival and final progression-free survival data for patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the ALEX study
- (2020) T. Mok et al. ANNALS OF ONCOLOGY
- Proteomic Analyses Identify a Novel Role for EZH2 in the Initiation of Cancer Cell Drug Tolerance
- (2020) Victoria Pham et al. JOURNAL OF PROTEOME RESEARCH
- Inhibition of Wnt/β-catenin pathway reverses multi-drug resistance and EMT in Oct4+/Nanog+ NSCLC cells
- (2020) Liyun Liu et al. BIOMEDICINE & PHARMACOTHERAPY
- Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing
- (2020) Ashley Maynard et al. CELL
- A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components
- (2020) Monique B. Nilsson et al. Science Translational Medicine
- AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
- (2019) Hirokazu Taniguchi et al. Nature Communications
- Patient-specific tumor growth trajectories determine persistent and resistant cancer cell populations during treatment with targeted therapies
- (2019) Clemens Grassberger et al. CANCER RESEARCH
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- (2019) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
- (2019) Sana Raoof et al. ONCOGENE
- Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition
- (2019) Meagan B. Ryan et al. CLINICAL CANCER RESEARCH
- The great escape: tumour cell plasticity in resistance to targeted therapy
- (2019) Soufiane Boumahdi et al. NATURE REVIEWS DRUG DISCOVERY
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
- (2019) Suresh S. Ramalingam et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adaptive mutability of colorectal cancers in response to targeted therapies
- (2019) Mariangela Russo et al. SCIENCE
- Tumor Architecture and Notch Signaling Modulate Drug Response in Basal Cell Carcinoma
- (2018) Markus Eberl et al. CANCER CELL
- Toward Minimal Residual Disease-Directed Therapy in Melanoma
- (2018) Florian Rambow et al. CELL
- Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B
- (2018) Mikkel Staberg et al. Molecular Oncology
- Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
- (2018) Dietrich A. Ruess et al. NATURE MEDICINE
- Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
- (2018) Gabrielle S. Wong et al. NATURE MEDICINE
- SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
- (2018) Sara Mainardi et al. NATURE MEDICINE
- Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors
- (2018) Julia Boshuizen et al. NATURE MEDICINE
- Mechanism of ECM-induced dormancy and chemoresistance in A549 human lung carcinoma cells
- (2018) Siriporn Keeratichamroen et al. ONCOLOGY REPORTS
- Single-cell Wnt signaling niches maintain stemness of alveolar type 2 cells
- (2018) Ahmad N. Nabhan et al. SCIENCE
- Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E -Mutant Colorectal Cancer
- (2018) Ryan B. Corcoran et al. Cancer Discovery
- Epigenetic and Transcriptomic Profiling of Mammary Gland Development and Tumor Models Disclose Regulators of Cell State Plasticity
- (2018) Christopher Dravis et al. CANCER CELL
- Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4
- (2018) Francesca Zanconato et al. NATURE MEDICINE
- Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities
- (2018) Satoshi Yoda et al. PHARMACOLOGY & THERAPEUTICS
- Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
- (2018) Rajeswara Rao Arasada et al. Nature Communications
- Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer
- (2018) Tyler Risom et al. Nature Communications
- Dormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer
- (2018) François M. Vallette et al. BIOCHEMICAL PHARMACOLOGY
- KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance
- (2018) Kunihiko Hinohara et al. CANCER CELL
- A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition
- (2018) Brian Biehs et al. NATURE
- A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy
- (2018) Adriana Sánchez-Danés et al. NATURE
- Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer
- (2018) Khyati N. Shah et al. NATURE MEDICINE
- Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade
- (2017) Hui-wen Lue et al. GENES & DEVELOPMENT
- Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
- (2017) Sydney M. Shaffer et al. NATURE
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition
- (2017) Matthew J. Hangauer et al. NATURE
- Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
- (2017) Vasanthi S. Viswanathan et al. NATURE
- EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
- (2017) Tsukasa Shibue et al. Nature Reviews Clinical Oncology
- Marked for death: targeting epigenetic changes in cancer
- (2017) Sophia Xiao Pfister et al. NATURE REVIEWS DRUG DISCOVERY
- Persistent bacterial infections and persister cells
- (2017) Robert A. Fisher et al. NATURE REVIEWS MICROBIOLOGY
- Epigenetic plasticity and the hallmarks of cancer
- (2017) William A. Flavahan et al. SCIENCE
- Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex
- (2017) Jon S. Zawistowski et al. Cancer Discovery
- Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression
- (2017) Maria Rusan et al. Cancer Discovery
- Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells
- (2016) Isao Kobayashi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells
- (2016) Maia Vinogradova et al. Nature Chemical Biology
- A framework for understanding and targeting residual disease in oncogene-driven solid cancers
- (2016) Trever G Bivona et al. NATURE MEDICINE
- Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
- (2016) Aaron N Hata et al. NATURE MEDICINE
- Distinguishing between resistance, tolerance and persistence to antibiotic treatment
- (2016) Asher Brauner et al. NATURE REVIEWS MICROBIOLOGY
- The induction of MIG6 under hypoxic conditions is critical for dormancy in primary cultured lung cancer cells with activating EGFR mutations
- (2016) H Endo et al. ONCOGENE
- Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells
- (2016) Michael Ramirez et al. Nature Communications
- Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling
- (2015) Eishu Hirata et al. CANCER CELL
- The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma
- (2015) Barbara Banelli et al. CELL CYCLE
- The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
- (2015) M. J. Niederst et al. CLINICAL CANCER RESEARCH
- Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin
- (2015) Matthew G Oser et al. LANCET ONCOLOGY
- Studying clonal dynamics in response to cancer therapy using high-complexity barcoding
- (2015) Hyo-eun C Bhang et al. NATURE MEDICINE
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- (2015) David M. Hyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Persisters unmasked
- (2015) D. W. Holden SCIENCE
- Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition
- (2015) Aaron Goldman et al. Nature Communications
- The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
- (2015) A. N. Hata et al. Cancer Discovery
- Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
- (2015) Z. Piotrowska et al. Cancer Discovery
- NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer
- (2015) Collin M. Blakely et al. Cell Reports
- Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways
- (2015) S Michael Rothenberg et al. eLife
- Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells
- (2014) Ho-June Lee et al. CANCER CELL
- Phenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy
- (2014) K. Kemper et al. CANCER RESEARCH
- The Cancer Stem Cell Marker Aldehyde Dehydrogenase Is Required to Maintain a Drug-Tolerant Tumor Cell Subpopulation
- (2014) D. Raha et al. CANCER RESEARCH
- Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
- (2014) Chong Sun et al. NATURE
- Alveolar progenitor and stem cells in lung development, renewal and cancer
- (2014) Tushar J. Desai et al. NATURE
- Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
- (2014) Nicholas Kwiatkowski et al. NATURE
- Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
- (2014) Andrea Viale et al. NATURE
- An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia
- (2014) Birgit Knoechel et al. NATURE GENETICS
- A stress-induced early innate response causes multidrug tolerance in melanoma
- (2014) D Ravindran Menon et al. ONCOGENE
- PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling
- (2014) S E Moody et al. ONCOGENE
- Hypoxia Increases Gefitinib-Resistant Lung Cancer Stem Cells through the Activation of Insulin-Like Growth Factor 1 Receptor
- (2014) Akiko Murakami et al. PLoS One
- Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
- (2014) Judith Müller et al. Nature Communications
- Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells
- (2013) Alexander Roesch et al. CANCER CELL
- High T790M Detection Rate in TKI-Naive NSCLC with EGFR Sensitive Mutation: Truth or Artifact?
- (2013) Xin Ye et al. Journal of Thoracic Oncology
- Rethinking the war on cancer
- (2013) Douglas Hanahan LANCET
- A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
- (2013) Cory M. Johannessen et al. NATURE
- Microenvironmental regulation of tumor progression and metastasis
- (2013) Daniela F Quail et al. NATURE MEDICINE
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- (2013) H. Shi et al. Cancer Discovery
- Mechanisms of Metastatic Tumor Dormancy
- (2013) Mary Osisami et al. Journal of Clinical Medicine
- Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer
- (2012) Kang-Yi Su et al. JOURNAL OF CLINICAL ONCOLOGY
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- A restricted cell population propagates glioblastoma growth after chemotherapy
- (2012) Jian Chen et al. NATURE
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
- (2012) Ryan B. Corcoran et al. Cancer Discovery
- MET-Independent Lung Cancer Cells Evading EGFR Kinase Inhibitors Are Therapeutically Susceptible to BH3 Mimetic Agents
- (2011) W. Fan et al. CANCER RESEARCH
- Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells
- (2011) Piyush B. Gupta et al. CELL
- FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
- (2011) Trever G. Bivona et al. NATURE
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- (2010) Alexa B. Turke et al. CANCER CELL
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth
- (2010) Alexander Roesch et al. CELL
- Therapy-Induced Senescence in Cancer
- (2010) Jonathan A. Ewald et al. JNCI-Journal of the National Cancer Institute
- EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
- (2010) A Singh et al. ONCOGENE
- TGF- IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer
- (2010) Z. Yao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
- (2009) W. Wang et al. CLINICAL CANCER RESEARCH
- In vivo Switching of Human Melanoma Cells between Proliferative and Invasive States
- (2008) K. S. Hoek et al. CANCER RESEARCH
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
- (2008) C.-H. Yun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mechanisms of Disease: cancer stem cells—targeting the evil twin
- (2008) Andreas Trumpp et al. Nature clinical practice. Oncology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now